ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, uncontrolled, phase II trial aimed to establish the
safety and tolerability of venetoclax, atezolizumab and obinutuzumab combination in Richter
Transformation of CLL.